SCHEMBL4356148

SCHEMBL4356148

CC(C)(C)c1ccc(NC2=NC(=O)CS2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.42
CYP1A2 P05177 1/20 0.42
KMT2A Q03164 6/20 0.41
NPC1 O15118 6/20 0.41
RAB9A P51151 6/20 0.41
LMNA P02545 2/20 0.41
TP53 P04637 2/20 0.41
PKM P14618 1/20 0.41
NFKB1 P19838 1/20 0.41
NFKB2 Q00653 1/20 0.41
RELA Q04206 1/20 0.41
SMN1; SMN2 Q16637 4/20 0.40
ALDH1A1 P00352 2/20 0.40
HPGD P15428 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
DHODH Q02127 2/20 0.39
MEN1 O00255 3/20 0.39
MAPT P10636 2/20 0.38
GAA P10253 1/20 0.38
PTGIR P43119 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL49741 0.69 TSHR (0.52) KMT2ANPC1RAB9ALMNASMN1; SMN2
SCHEMBL2392625 0.69 TSHR (0.52) KMT2ANPC1RAB9ALMNASMN1; SMN2
SCHEMBL24243522 0.66 CYP1A2 (0.39) POLBCYP1A2KMT2ALMNASMN1; SMN2
SCHEMBL25888283 0.65 NPC1 (0.43) KMT2ANPC1RAB9ALMNASMN1; SMN2
SCHEMBL17503412 0.65 KDR (0.48) NPC1RAB9ASMN1; SMN2DHODHMAPT
SCHEMBL6330698 0.65 ALDH1A1 (0.34) POLBKMT2ANPC1RAB9ATP53
SCHEMBL5396983 0.63 TSHR (0.46) KMT2ANPC1RAB9ALMNASMN1; SMN2
SCHEMBL2957181 0.63 KIF11 (0.57) KMT2ANPC1RAB9ALMNASMN1; SMN2
SCHEMBL22432523 0.63 TSHR (0.46) KMT2ANPC1RAB9ALMNASMN1; SMN2
SCHEMBL13321302 0.63 KIF11 (0.57) KMT2ANPC1RAB9ALMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1890695-B1 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS GRUENENTHAL GMBH (DE) 2013-02-20 EP disclosed
EP-1890695-B1 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS GRUENENTHAL GMBH (DE) 2013-02-20 EP disclosed
US-20090215758-A1 Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs GRUENENTHAL GMBH (DE) 2009-08-27 US disclosed
US-20090215758-A1 Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs GRUENENTHAL GMBH (DE) 2009-08-27 US disclosed
US-20090215758-A1 Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs GRUENENTHAL GMBH (DE) 2009-08-27 US disclosed
EP-1890695-A2 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS Grünenthal GmbH (DE) 2008-02-27 EP disclosed
WO-2006122777-A2 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS Grünenthal GmbH (DE) 2006-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215758-A1 Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs ABCB1, ABCG2, SLC5A2 POLB 4427/4885CYP1A2 162/4885KMT2A 3923/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.